June 17, 2021
European Journal of Human Genetics (vol. 28, no. 8, 2018) is available online by subscription only. Articles include: “Willingness to Donate Genomic and Other Medical Data: Results from Germany” by Torsten H. Voigt, et al. “How the ‘Control-Fate Continuum’ helps … Read More
June 11, 2021
(Axios) – Two Biogen executives said in an interview the company’s newly approved Alzheimer’s drug is priced fairly, and that it didn’t conduct another clinical trial before approval because the FDA didn’t push them to do so. Why it matters: … Read More
June 10, 2021
(STAT News) – A third member of a Food and Drug Administration expert panel has resigned over the agency’s contentious approval of an Alzheimer’s therapy this week, a sign of a growing backlash over the decision. In a letter to … Read More
June 9, 2021
(STAT News) – Following the Food and Drug Administration’s polarizing authorization of the Alzheimer’s therapy Aduhelm on Monday, a member of an agency advisory committee that recommended against the drug’s approval has resigned. Neurologist Joel Perlmutter of Washington University in … Read More
June 9, 2021
The Linacre Quarterly (vol. 87, no. 3, 2020) is available online by subscription only. Articles include: Testing for Down Syndrome in Catholic Health Care: Complicity in Eugenic Abortion” by James G. Linn “Women’s Reproductive Health Education in Catholic Academic Healthcare … Read More
June 7, 2021
(STAT News) – The Food and Drug Administration on Monday approved the first new treatment for Alzheimer’s disease in nearly two decades, a landmark decision that has been eagerly awaited by millions of Americans diagnosed with the condition but that … Read More
June 7, 2021
Genetics in Medicine (vol. 22, no. 6, 2020) is available online by subscription only. Articles include: “Blood RNA Analysis can Increase Clinical Diagnostic Rate and Resolve Variants of Uncertain Significance” by Htoo A. Wai, et al. “The Cardiac Genome Clinic: … Read More
June 4, 2021
(New York Times) – Forty-eight people from the same small Canadian province struck with a baffling mix of symptoms including insomnia, impaired motor function and hallucinations such as nightmarish visions of the dead. A quixotic neurologist working 12-hour days to … Read More
June 4, 2021
(Axios) – The FDA will soon decide the fate of Biogen’s experimental Alzheimer’s drug. But there is one glaring issue — there is no conclusive evidence the drug effectively treats the crippling neurological disease. Why it matters: This will be … Read More
June 3, 2021
The Journal of Law, Medicine & Ethics (vol. 48, no. 2, 2019) is available online by subscription only. Articles include: “Opioids May be Appropriate for Chronic Pain” by Paul J. Christo “An Effective Intervention: Limiting Opioid Prescribing as a Means … Read More
